A premier producer of high-quality, low-cost, sun-grown cannabis flower, oil cannabinoids and hemp-based extracts and derivatives, serving domestic markets.
Uniquely Situated
Located between two intersecting valleys near the US border in lower interior British Columbia, our unique climate presents some of the finest grow conditions in North America.
Master Growers
With decades of outdoor cannabis cultivation experience, our team is delivering premium-quality flower at industry-low production costs.
Proprietary Genetics
We’ve developed proprietary high-yield, high-potency strains proven to thrive in our unique environment.
On-site Extraction and Processing
Ultra-efficient production of premium-quality cannabis extracts suitable for 1000s of possible product applications.
Room to Grow
99 acres of fully owned expansion space, a strong capital foundation, a scalable low-cost production model, and a variety of domestic and global business opportunities all uniquely position Christina Lake Cannabis Corp for growth.
News
Christina Lake Cannabis Announces Filing of Q1 Financial Statements
Join our mailing list
Contact Us
Head Office
Suite 810
789 West Pender Street
Vancouver, BC
V6C 1H2
Ph: 1.604.687.2038
Investor Inquiries
Ph: 1.888.410.0304
investors@clcannabis.com
Operations
Christina Lake, BC
Ph: 1.866.561.4554
Cautionary / Privacy Policy
Forward-Looking Information
Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, “forward-looking statements”).
Such forward-looking statements relate to possible events, conditions or financial performance of the Company based on future economic conditions and courses of action.
All statements other than statements of historical fact are forward-looking statements.
The use of any words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “will likely result”, “are expected to”, “will continue”, “is anticipated”, “believes”, “estimated”, “intends”, “plans”, “projection”, “outlook” and similar expressions are intended to identify forward-looking statements.
These statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.
The Company believes there is a reasonable basis for the expectations reflected in the forward-looking statements, however no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this presentation should not be unduly relied upon by investors.
The forward-looking statements speak only as of the date of this presentation and are expressly qualified, in their entirety, by this cautionary statement.
In addition, the Company’s assessment of, and targets for, sales of hemp-derived CBD products, expansion of retail locations through which the Company’s products may be sold, expansion of the Company’s distribution channels, including overseas distribution, development of improvements to the Company’s products and related bioavailability technology, the isolation of additional cannabinoid products, annual revenue, and Adjusted EBITDA, are considered forward-looking statements.
The forward-looking statements and other forward-looking information are based on management’s opinions, estimates and assumptions in light of our experience and perception of historical trends, current trends, current conditions and expected future developments, as well as other factors that management currently believes appropriate and reasonable in the circumstances.
Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct.
For further details on the forward-looking statements included in this presentation, see “Forward-Looking Statements” and “Forward-Looking Statements relating to Growth Strategy”.
All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements.
Investors should read the entire prospectus and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their investment in any securities of the Company.
Non-IFRS Measures and Industry Metrics
This presentation makes reference to certain non-IFRS measures including key performance indicators used by management.
These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies.
Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective.
Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS.
The Company uses non-IFRS measures including “EBITDA” and “Adjusted EBITDA” which may be calculated differently by other companies.
These non-IFRS measures and metrics are used to provide investors with supplemental measures of the Company’s operating performance and liquidity and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures.
The Company also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of companies in similar industries.
Management also uses non-IFRS measures and metrics, in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of executive compensation.
Prospective investors should review the section entitled “Management’s Discussion and Analysis” in the prospectus for a discussion of the use of “EBITDA” and “Adjusted EBITDA” and reconciliations thereof to the most directly comparable IFRS measures.